Brawn Biotech
BSE: BRAWN · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Brawn Biotech's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Brawn Biotech Limited is an Indian pharmaceutical company that manufactures, markets, and exports a diverse range of healthcare products. Its portfolio includes antibiotics, cardiovascular drugs, and nutritional supplements across various dosage forms like tablets and injections.
Business Model
The company generates revenue through the production and sale of affordable generic medicines in both domestic and international markets. It leverages manufacturing facilities compliant with international quality standards to support its export operations in Southeast Asia, Africa, and the Middle East.
Growth Outlook
Brawn Biotech aims to expand its global footprint by pursuing strategic product registrations and establishing new distribution partnerships in international markets.
Key Risks
- Regulatory Compliance. The company faces risks related to maintaining international quality standards across its manufacturing facilities to ensure continued export eligibility.
- Pricing Pressure. Intense competition in the generic pharmaceutical sector may exert downward pressure on profit margins for the company's affordable medicine offerings.
- Geopolitical Instability. Operating in diverse international markets like Africa and the Middle East exposes the company to currency fluctuations and regional political risks.
- Supply Chain Disruptions. Reliance on global supply chains for raw materials and active pharmaceutical ingredients could impact production timelines and costs.
Start your research today
Unlock AI insights, financials, peers and live data on Brawn Biotech and 5,000+ companies — free.
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Brawn BiotechBRAWN | ₹7 Cr | — | — | — | -2.1% | — | — | +2.4% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Mar 2023
Financials
Brawn Biotech
BSE: BRAWN · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Brawn Biotech's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Brawn Biotech Limited is an Indian pharmaceutical company that manufactures, markets, and exports a diverse range of healthcare products. Its portfolio includes antibiotics, cardiovascular drugs, and nutritional supplements across various dosage forms like tablets and injections.
Business Model
The company generates revenue through the production and sale of affordable generic medicines in both domestic and international markets. It leverages manufacturing facilities compliant with international quality standards to support its export operations in Southeast Asia, Africa, and the Middle East.
Growth Outlook
Brawn Biotech aims to expand its global footprint by pursuing strategic product registrations and establishing new distribution partnerships in international markets.
Key Risks
- Regulatory Compliance. The company faces risks related to maintaining international quality standards across its manufacturing facilities to ensure continued export eligibility.
- Pricing Pressure. Intense competition in the generic pharmaceutical sector may exert downward pressure on profit margins for the company's affordable medicine offerings.
- Geopolitical Instability. Operating in diverse international markets like Africa and the Middle East exposes the company to currency fluctuations and regional political risks.
- Supply Chain Disruptions. Reliance on global supply chains for raw materials and active pharmaceutical ingredients could impact production timelines and costs.
Start your research today
Unlock AI insights, financials, peers and live data on Brawn Biotech and 5,000+ companies — free.
Peers · Pharmaceuticals
As of Mar 2023